Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Limited informed the BSE that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA, and 1.50% each of the equity shares of common stock of Med Therapy by Chairman & Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta, is currently under due diligence and pending confirmation from the Med Therapy Board of Directors decision and Board of Directors resolution.

Sudarshan Pharma Industries Limited announced that its board approved the acquisition of 24,23,675.64 equity shares, representing 9.50% of the issued and outstanding share capital, of MedTherapy Biotechnology Inc., a U.S.-based cancer cell and gene therapy company founded in 2018. Additionally, Chairman & Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta will acquire 3,82,685.63 shares each, equivalent to 1.50% each, of MedTherapy Biotechnology Inc. The acquisition, to be completed by March 31, 2027, will be funded with a cash consideration in U.S. dollars and requires approval under the Foreign Exchange Management Act, 1999.

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 18 June 2026.

Sudarshan Pharma Industries has revised the meeting of the Board of Directors which was scheduled to be held on 22 May 2026. The meeting will now be held on 21 May 2026.

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 15 May 2026.

Net profit of Sudarshan Pharma Industries rose 44.80% to Rs 10.73 crore in the quarter ended March 2026 as against Rs 7.41 crore during the previous quarter ended March 2025. Sales rose 36.72% to Rs 220.92 crore in the quarter ended March 2026 as against Rs 161.59 crore during the previous quarter ended March 2025. For the full year,net profit rose 55.64% to Rs 23.30 crore in the year ended March 2026 as against Rs 14.97 crore during the previous year ended March 2025. Sales rose 39.21% to Rs 703.06 crore in the year ended March 2026 as against Rs 505.04 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales220.92161.59 37 703.06505.04 39 OPM %9.149.86 -7.307.73 - PBDT16.8012.37 36 34.3325.64 34 PBT15.7011.54 36 30.5422.84 34 NP10.737.41 45 23.3014.97 56 Powered by Capital Market - Live

Net profit of Sudarshan Pharma Industries rose 35.70% to Rs 9.54 crore in the quarter ended March 2026 as against Rs 7.03 crore during the previous quarter ended March 2025. Sales rose 23.67% to Rs 199.81 crore in the quarter ended March 2026 as against Rs 161.57 crore during the previous quarter ended March 2025. For the full year,net profit rose 56.78% to Rs 21.98 crore in the year ended March 2026 as against Rs 14.02 crore during the previous year ended March 2025. Sales rose 32.84% to Rs 667.50 crore in the year ended March 2026 as against Rs 502.49 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales199.81161.57 24 667.50502.49 33 OPM %9.159.42 -7.347.47 - PBDT14.2311.69 22 32.0824.32 32 PBT13.2310.93 21 28.6721.62 33 NP9.547.03 36 21.9814.02 57 Powered by Capital Market - Live

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 30 April 2026.

Net profit of Sudarshan Pharma Industries rose 51.39% to Rs 4.36 crore in the quarter ended December 2025 as against Rs 2.88 crore during the previous quarter ended December 2024. Sales rose 45.26% to Rs 168.01 crore in the quarter ended December 2025 as against Rs 115.66 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales168.01115.66 45 OPM %6.476.90 - PBDT6.114.48 36 PBT5.203.85 35 NP4.362.88 51 Powered by Capital Market - Live

Sudarshan Pharma Industries will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live